Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Phase 2 Active not recruiting 18 enrolled Washington University School of Medicine

NaSingle-groupOpen-labelTreatment

Summary

This is a research study testing a new approach to treating high-risk non-Hodgkin's lymphoma consisting of an autologous hematopoietic (blood) stem cell transplant (using a patient's own hematopoietic cells) followed by a non-myeloablative allogeneic transplantation (transplant from another individual). The investigators hypothesize that the addition of the second non-myeloablative transplant will improve the chances for long-term control of lymphoma.

Timeline

Start: 2009-05-05
Primary completion: 2028-06-01
Completion: 2028-06-01

Publications

Background Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003 Nov 1;102(9):3447-54. doi: 10.1182/blood-2002-09-2955. Epub 2003 Jul 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Protein / enzyme biologic	1.5 mg/kg	—
Background	Methylprednisolone	Other / unclassified	1 mg/kg	—
Background	Mycophenolate Mofetil	Small molecule	15 mg/kg	Oral
Background	Tacrolimus	Small molecule	0.3 mg/kg	Oral

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications